Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for TScan Therapeutics (TCRX) over the last 6 years, with Q2 2025 value amounting to $116000.0.

  • TScan Therapeutics' Cash from Financing Activities fell 9992.82% to $116000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $45.3 million, marking a year-over-year decrease of 7223.63%. This contributed to the annual value of $208.8 million for FY2024, which is 5413.49% up from last year.
  • According to the latest figures from Q2 2025, TScan Therapeutics' Cash from Financing Activities is $116000.0, which was down 9992.82% from -$525000.0 recorded in Q1 2025.
  • TScan Therapeutics' Cash from Financing Activities' 5-year high stood at $161.6 million during Q2 2024, with a 5-year trough of -$686000.0 in Q2 2021.
  • Moreover, its 5-year median value for Cash from Financing Activities was $118000.0 (2021), whereas its average is $26.7 million.
  • In the last 5 years, TScan Therapeutics' Cash from Financing Activities skyrocketed by 906070000.0% in 2021 and then tumbled by 30348.84% in 2025.
  • TScan Therapeutics' Cash from Financing Activities (Quarter) stood at $120000.0 in 2021, then dropped by 10.0% to $108000.0 in 2022, then plummeted by 82.41% to $19000.0 in 2023, then surged by 240373.68% to $45.7 million in 2024, then tumbled by 99.75% to $116000.0 in 2025.
  • Its last three reported values are $116000.0 in Q2 2025, -$525000.0 for Q1 2025, and $45.7 million during Q4 2024.